GlaxoSmithKline_NN
176_CD
Share_NN
capital_NN
Nature_NN
of_PIN
trading_GER
market_NN
Glaxo_NN
Wellcome_NN
The_NN
Ordinary_NN
Shares_NN
of_PIN
the_DT
company_NN
were_VBD [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Fiscal_JJ
period_NN
from_PIN
1st_CD
January_NN
to_PIN
26th_JJ
December_NN
2000_CD
Stock_NN
Exchange_NN
on_PIN
27th_JJ
December_NN
2000_CD
._.
The_DT
shares_NN
were_VBD
also_RB
Pence_NN
per_PIN
share_NN
listed_VBN [WZPAST]
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
in_PIN
the_DT
form_NN
of_PIN
American_NN
High_NN
Low_NN
Depositary_NN
Shares_NN
ADSs_NN
from_PIN
the_DT
same_JJ
date_NN
._.
2000 2110 1440_CD
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN [STPR]
,_,
for_PIN
the_DT
periods_NN
indicated_VBD [PRIV]
,_,
the_DT
high_JJ
and_PHC
low_JJ
middle_JJ
market_NN
closing_VBG [WZPRES]
quotations_NOMZ
in_PIN
pence_NN
for_PIN
the_DT
shares_NN
Fiscal_JJ
period_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
,_,
as_IN
derived_VBN
from_PIN
its_PIT
Daily_NN
Official_NN
from_PIN
1st_CD
January_NN
to_PIN
26th_JJ
December_NN
2000_CD
US_FPP1
dollars_NN
per_PIN
ADS_NN
List_NN
,_,
and_ANDC
the_DT
high_JJ
and_PHC
low_JJ
last_JJ
reported_VBD [PUBV]
sales_NN
prices_NN
in_PIN
US_FPP1
dollars_NN
for_PIN
the_DT
ADSs_NN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
,_,
as_IN
derived_VBN
from_PIN
High_NN
Low_NN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
Composite_NN
Tape_NN
._.
3_CD
2000_CD
63_CD
4_CD
46_CD
Information_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
share_NN
and_PHC
ADS_NN
prices_NN
for_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
prior_RB
to_PIN
the_DT
date_NN
of_PIN
SmithKline_NN
Beecham_NN
the_DT
merger_NN
is_VPRT [SPAU] [PASS]
also_RB
given_VBN
._.
At_PIN
25th_JJ
February_NN
2005_CD
,_,
the_DT
number_NN
of_PIN
holders_NN
of_PIN
record_NN
of_PIN
shares_NN
in_PIN
the_DT
USA_NN
was_VBD [BEMA]
1,187_CD
with_PIN
holdings_GER
of_PIN
1,776,334_CD
shares_NN
,_,
and_ANDC
the_DT
number_NN
of_PIN
registered_VBN
holders_NN
of_PIN
the_DT
ADRs_NN
was_VBD [BEMA]
44,537_CD
with_PIN
holdings_GER
of_PIN
401,140,809_CD
ADRs_NN
._.
Certain_NN
of_PIN
these_DEMO
shares_NN
and_PHC
ADRs_NN
were_VBD [BYPA]
held_VBN [PRIV]
by_PIN
brokers_NN
or_CC
other_JJ
nominees_NN
,_,
as_CONJ
a_NULL
result_NULL
the_DT
number_NN
of_PIN
holders_NN
of_PIN
record_NN
or_CC
registered_VBN
holders_NN
in_PIN
the_DT
USA_NN
is_VPRT [BEMA]
not_XX0
representative_PRED
of_PIN
the_DT
number_NN
of_PIN
beneficial_JJ
holders_NN
or_CC
of_PIN
the_DT
residence_NN
of_PIN
beneficial_JJ
holders_NN
._.
Control_NN
of_PIN
company_NN
As_IN
far_PLACE
as_RB
is_VPRT [PASS]
known_VBN [PRIV]
to_PIN
the_DT
company_NN
,_,
it_PIT
is_VPRT
not_XX0
directly_RB
or_CC
indirectly_RB
owned_VBN
or_CC
controlled_VBN
by_PIN
one_CD
or_CC
more_EMPH
corporations_NOMZ
or_CC
by_PIN
any_QUAN
government_NOMZ
._.
The_DT
company_NN
does_VPRT
not_XX0
know_VB [PRIV]
of_PIN
any_QUAN
arrangements_NOMZ
,_,
the_DT
operation_NOMZ
of_PIN
which_WDT [PIRE]
might_POMD
result_VB
in_PIN
a_DT
change_NN
in_PIN
control_NN
of_PIN
the_DT
company_NN
._.
Substantial_JJ
shareholdings_GER
At_PIN
25th_JJ
February_NN
2005_CD
,_,
the_DT
company_NN
had_VBD [PEAS]
received_VBN
notification_NOMZ
of_PIN
the_DT
following_VBG
interests_NN
of_PIN
three_CD
per_PIN
cent_NN
or_CC
more_EMPH
in_PIN
the_DT
shares_NN
in_PIN
issue_NN
,_,
excluding_VBG
Treasury_NN
shares_NN
:_:
BNY_NN
Nominees_NN
Limited_NN
holds_VPRT [PRIV] [THATD]
802,281,619_CD
shares_NN
representing_VBG [WZPRES]
13.68_CD
per_PIN
cent_NN
._.
These_DEMO
shares_NN
are_VPRT [PASS]
held_VBN [PRIV]
on_PIN
behalf_NN
of_PIN
holders_NN
of_PIN
ADRs_NN
,_,
which_WDT [SERE]
evidence_NN
ADSs_NN
._.
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
Limited_NN
holds_VPRT [PRIV] [THATD]
215,495,981_CD
shares_NN
representing_VBG [WZPRES]
3.67_CD
per_PIN
cent_NN
._.
Barclays_NN
plc_NN
holds_VPRT [PRIV] [THATD]
229,512,017_CD
shares_NN
representing_VBG [WZPRES]
3.91_CD
per_PIN
cent_NN
._.
As_IN
far_PLACE
as_RB
is_VPRT [PASS]
known_VBN [PRIV]
to_PIN
the_DT
company_NN
,_,
no_SYNE
other_JJ
person_NN
was_VBD [BEMA]
the_DT
owner_NN
of_PIN
three_CD
per_PIN
cent_NN
or_CC
more_EMPH
of_PIN
the_DT
shares_NN
in_PIN
issue_NN
,_,
excluding_VBG
Treasury_NN
shares_NN
of_PIN
the_DT
company_NN
._.
Directors_NN
and_PHC
Officers_NN
The_DT
interests_NN
of_PIN
the_DT
Directors_NN
and_PHC
Officers_NN
of_PIN
the_DT
company_NN
,_,
as_IN
defined_VBN
in_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
in_PIN
share_NN
options_NOMZ
of_PIN
the_DT
company_NN
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
pages_NN
43_CD
to_PIN
58_CD
._.
Exchange_NN
controls_NN
and_CC
other_JJ
limitations_NOMZ
affecting_VBG [WZPRES]
security_NOMZ
holders_NN
There_EX
are_VPRT
currently_RB
no_SYNE
UK_NN
laws_NN
,_,
decrees_NN
or_CC
regulations_NOMZ
restricting_VBG [WZPRES]
the_DT
import_NN
or_CC
export_NN
of_PIN
capital_NN
or_CC
affecting_VBG
the_DT
remittance_NN
of_PIN
dividends_NN
or_CC
other_JJ
payments_NOMZ
to_PIN
holders_NN
of_PIN
the_DT
companys_NN
shares_NN
who_WP [WHSUB]
are_VPRT
non-residents_NN
of_PIN
the_DT
UK_NN
._.
There_EX
are_VPRT
no_SYNE
limitations_NOMZ
relating_VBG [WZPRES]
only_DWNT
to_PIN
non-residents_NN
of_PIN
the_DT
UK_NN
under_IN
English_NN
law_NN
or_CC
the_DT
companys_NN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
on_PIN
the_DT
right_NN
to_TO
be_VB [BEMA]
a_DT
holder_NN
of_PIN [STPR]
,_,
and_ANDC
to_TO
vote_VB [SUAV]
in_PIN
respect_NN
of_PIN [STPR]
,_,
the_DT
companys_NN
shares_NN
._.
Documents_NOMZ
on_PIN
display_NN
The_DT
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
of_PIN
the_DT
company_NN
and_CC
other_JJ
documents_NOMZ
referred_VBD
to_PIN
in_PIN
this_DEMO
Annual_JJ
Report_NN
are_VPRT [BEMA]
available_PRED
for_PIN
inspection_NOMZ
at_PIN
the_DT
Registered_NN
Office_NN
of_PIN
the_DT
company_NN
._.
Publications_NOMZ
This_DEMO
year_NN
GlaxoSmithKline_NN
is_VPRT [SPAU]
again_TIME
producing_VBG
a_DT
Corporate_JJ
Responsibility_NOMZ
Report_NN
covering_VBG [WZPRES]
performance_NN
in_PIN
areas_NN
including_VBG [WZPRES]
community_NOMZ
investment_NOMZ
,_,
business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
,_,
access_NN
to_PIN
medicines_NN
,_,
R&D_NN
and_CC
environmental_JJ
health_NN
and_PHC
safety_NN
._.
The_DT
report_NN
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
the_DT
website_NN
at_PIN
the_DT
end_NN
of_PIN
March_NN
._.
